Firefly Neuroscience reports over 200,000 EEG/ERP scans, accelerating AI-driven biomarker discovery for neurological conditions.
Quiver AI Summary
Firefly Neuroscience, Inc. announced a significant milestone, surpassing 200,000 EEG/ERP brain scans, which reflects consistent sequential growth of 5%, 11%, 15%, and 17% over the past four quarters. This achievement is fueled by the company's acquisition of Evoke Neuroscience and its utilization of NVIDIA's L40S GPU acceleration to enhance EEG/ERP processing. With this progress, Firefly aims to develop the world's first EEG/ERP-based foundation model of the human brain, advancing capabilities in AI-driven biomarker discovery for various cognitive disorders, including ADHD and Alzheimer’s disease. The company’s proprietary database now is the largest known standardized EEG/ERP repository, positioning it to revolutionize diagnostic and treatment approaches in neuroscience.
Potential Positives
- Firefly has achieved a major operational milestone by surpassing 200,000 EEG/ERP brain scans, positioning itself as a leader in standardized EEG/ERP data collection.
- The company reported significant sequential growth in brain scan volumes over the past four quarters, indicating strong operational performance and market demand for its technology.
- Firefly's advancements in AI-driven biomarker discovery have the potential to improve diagnostic capabilities for various neurological disorders, enhancing patient outcomes.
- The goal of building and launching the world's first EEG/ERP-based foundation model of the human brain highlights Firefly's innovative approach and commitment to leading the field of precision neuroscience.
Potential Negatives
- The reliance on forward-looking statements introduces uncertainty regarding the company's future performance and potential risks that may affect its operations.
- The risks associated with the forward-looking statements could lead to actual results that differ significantly from the anticipated outcomes, impacting stakeholder confidence.
- The company's growth in brain scan volumes, while positive, might mask underlying challenges or limitations related to the scalability of its technology and market adoption.
FAQ
What milestone has Firefly achieved in EEG/ERP scans?
Firefly has surpassed 200,000 EEG/ERP brain scans, marking a significant operational and commercial milestone.
How has Firefly increased its scan volume?
Firefly's scan volumes have grown sequentially by 5%, 11%, 15%, and 17% over the past four quarters.
What technology is Firefly using for brain function analysis?
Firefly utilizes NVIDIA L40S GPU acceleration to enhance its EEG/ERP processing and biomarker discovery capabilities.
What is the goal of Firefly's EEG/ERP-based model?
Firefly aims to build and launch the world's first EEG/ERP-based foundation model of the human brain.
What conditions can Firefly's technology help diagnose?
Firefly's technology has the potential to aid in diagnosing conditions like depression, dementia, anxiety disorders, concussions, and ADHD.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AIFF Insider Trading Activity
$AIFF insiders have traded $AIFF stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $AIFF stock by insiders over the last 6 months:
- PRIVATE CAPITAL LP WINDSOR has made 0 purchases and 8 sales selling 295,064 shares for an estimated $725,380.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AIFF Revenue
$AIFF had revenues of $412K in Q4 2025. This is an increase of 677.36% from the same period in the prior year.
You can track AIFF financials on Quiver Quantitative's AIFF stock page.
$AIFF Hedge Fund Activity
We have seen 5 institutional investors add shares of $AIFF stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 66,015 shares (-72.8%) from their portfolio in Q4 2025, for an estimated $57,763
- JANE STREET GROUP, LLC added 60,315 shares (+inf%) to their portfolio in Q4 2025, for an estimated $52,775
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 37,742 shares (+inf%) to their portfolio in Q4 2025, for an estimated $33,024
- ADVISORY SERVICES NETWORK, LLC removed 31,344 shares (-48.9%) from their portfolio in Q4 2025, for an estimated $27,426
- SAVVY ADVISORS, INC. removed 21,500 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $18,812
- BLACKROCK, INC. added 8,798 shares (+11.4%) to their portfolio in Q4 2025, for an estimated $7,698
- MORGAN STANLEY removed 3,529 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,087
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
- Firefly’s total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters -
- Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, enabling new AI-driven biomarker discovery capabilities –
- Milestone supports Firefly’s goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain -
KENMORE, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce the achievement of a major operational and commercial milestone: over 200,000 EEG/ERP (human brain function) scans.
Through its acquisition of Evoke Neuroscience, Inc. in May 2025, combined with the successful execution of its key internal growth initiatives, Firefly has now driven 5%, 11%, 15%, and 17% sequential EEG/ERP brain scan volume growth, respectively, over the past four quarters.
“Surpassing this important milestone opens the door to us potentially making additional new breakthroughs in cognitive brain biomarker discovery, building upon those we’ve already recently made for differential diagnosis of ADHD , objective measurement of SCD/MCI/Dementia in Alzheimer's patients , and cognitive assessment of brain age ,” commented Firefly’s Chief Executive Officer, Greg Lipschitz. “In so doing, we also believe we are now much closer to fulfilling our goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
About Firefly
Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient's brain is functioning. Firefly’s proprietary database now consists of over 200,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
[email protected]